| 史蕾,王洋,孟雪,等.软肝化坚颗粒联合生物信息红外肝病治疗仪对慢性乙型肝炎病人抗肝纤维化疗效观察[J].安徽医药,2024,28(8):1599-1603. |
| 软肝化坚颗粒联合生物信息红外肝病治疗仪对慢性乙型肝炎病人抗肝纤维化疗效观察 |
| Ruangganhuajian granule combined with biological information infrared liver disease thera- peutic instrument clinical observation of anti-liver fibrosis in patients with chronic hepatitis B |
| |
| DOI：10.3969/j.issn.1009-6469.2024.08.024 |
| 中文关键词: 乙型肝炎，慢性 软肝化坚颗粒 生物信息红外肝病治疗仪 肝纤维化 |
| 英文关键词: Hepatitis B, chronic Ruanganhuajian granules Biological information infrared liver disease treatment instrument Liver fibrosis |
| 基金项目:河北省中医药管理局科研计划项目( 2014089) |
|
| 摘要点击次数: 508 |
| 全文下载次数: 440 |
| 中文摘要: |
| 目的探究软肝化坚颗粒联合生物信息红外肝病治疗仪对慢性乙型肝炎( CHB)病人抗肝纤维化的疗效。方法选取 2015年 2月至 2018年 5月石家庄市第五医院收治的 CHB病人 120例，分为对照组( 60例)和观察组( 60例)对照组采用生物信息红外肝病治疗仪治疗，观察组在对照组基础上联合软肝化坚颗粒。记录两组临床疗效、血清肝纤维化指标［，透明质酸( HA)、 Ⅲ型前胶原( PC-Ⅲ)、 Ⅳ型胶原( Ⅳ-C)、层黏连蛋白( LN)］，肝功能指标［谷丙转氨酶( ALT)、谷草转氨酶( AST)、总胆红素(TBiL)］、中医症候积分以及不良反应发生情况。结果治疗后，观察组总有效率( 90.00%)高于对照组( 72.50%)(P<0.05)；观察组血清 HA、LN、PC-Ⅲ、Ⅳ-C水平均低于对照组［( 93.34±36.62)mg/L比( 110.87±35.71)mg/L、(73.78±24.14)mg/L比( 85.31±25.62)mg/L、(84.72±23.75)mg/L比( 100.92±23.34)mg/L、(56.78±14.14)mg/L比( 77.47±15.22)mg/L］(P<0.05)；观察组 ALT、AST、 GGT及中医证候积分低于对照组( P<0.05)。两组不良反应发生率差异无统计学意义( P>0.05)。结论 CHB病人采用软肝化坚颗粒联合生物信息红外肝病治疗仪治疗，可有效缓解病人肝纤维化，改善肝功能，安全性高。 |
| 英文摘要: |
| Objective To explore the effect of Ruanganhuajian granule combined with biological information infrared liver disease treatment instrument on anti-liver fibrosis in patients with chronic hepatitis B.Methods A total of 120 patients with CHB admitted toThe Fifth Hospital of Shijiazhuang from February 2015 to May 2018. They were selected and divided into the observation group (60 cas-es) and the control group(60 cases). the control group was treated with biological information infrared liver disease treatment instru-ment, and the observation group was combined with Ruganhuajian granule on the basis of the control group. Record two groups of clini-cal curative effect, serum liver fibrosis indexes [hyaluronic acid (HA), type Ⅲ before collagen (PC-Ⅲ), collagen type Ⅳ (Ⅳ-C) laminin(LN)], liver function index [alanine aminotransferase (ALT), aspertate aminotransferase (AST), total bilirubin (TBiL)]. Two sets of TCMsyndrome scores and adverse reactions were recorded. Results After treatment, The total effective rate in the observation group (90.00%) was higher than that in the control group(72.50%) (P<0.05). The serum levels of HA, LN, PC-Ⅲ and Ⅳ-C in the observation group were lower than those in the control group[(93.34±36.62)mg/L vs. (110.87±35.71)mg/L, (73.78±24.14)mg/L vs. (85.31±25.62)mg/ L, (84.72±23.75)mg/L vs. (100.92±23.34)mg/L, (56.78±14.14)mg/L vs. (77.47±15.22) mg/L] (P<0.05). The scores of ALT, AST, GGT and TCM syndromes in the observation group were lower (P<0.05). There was no difference in the incidence of adverse reactions be- tween the two groups (P>0.05).Conclusion Ruanganhuajian granule combined with biological information infrared liver disease treat-ment instrument for CHB patients can effectively alleviate liver fibrosis and improve liver function, with high safety. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
